STOCK TITAN

Vaxcyte officer plans sale of about $1.15M in shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Vaxcyte, Inc. officer Harpreet S. Dhaliwal reported a planned sale of 17,000 common shares, with an approximate market value of $1,153,101.50 and an approximate sale date of November 11, 2026. Dhaliwal acquired 17,000 common shares through an exercise of stock options on November 11, 2026, with cash payment.

Dhaliwal also reported a sale during the prior three months of 17,000 common shares on August 5, 2026, for gross proceeds of $935,066.15. The reported Rule 10b5-1 plan adoption or instruction date is April 6, 2026.

Planned sale 17,000 common shares Approximate sale date November 11, 2026
Aggregate market value $1,153,101.50 Planned sale
Shares outstanding 158,299,981 common shares Listed in the notice
Prior sale 17,000 common shares Sale date August 5, 2026
Gross proceeds $935,066.15 Sale on August 5, 2026
Option exercise 17,000 common shares Acquired November 11, 2026, with cash payment
Rule 10b5-1 regulatory
"Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Aggregate Market Value financial
"Number of Shares or Other Units To Be Sold | Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Exercise of Stock Options financial
"Nature of Acquisition Transaction | Exercise of Stock Options"
Gross Proceeds financial
"Amount of Securities Sold | Gross Proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Vaxcyte shares does officer Harpreet S. Dhaliwal plan to sell?

Harpreet S. Dhaliwal reported a planned sale of 17,000 common shares, with an approximate market value of $1,153,101.50 and an approximate sale date of November 11, 2026. The shares were acquired through an exercise of stock options on November 11, 2026, with cash payment.

What previous Vaxcyte share sale did Harpreet S. Dhaliwal report?

Dhaliwal reported a sale of 17,000 common shares on August 5, 2026, for gross proceeds of $935,066.15. The sale was included among securities sold during the prior three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading